Interrad Medical’s SecurAcath Reduces Catheter Dislodgement and Saves Costs in Pediatric Patients

Interrad Medical, Inc. has achieved significant success with its SecurAcath device, as demonstrated in a recent clinical study published in JAMA Pediatrics. The study, titled “Securement to prevent non-cuffed central venous catheter dislodgement in pediatrics: The SECURED superiority randomized clinical trial,” conducted in partnership with The Queensland Children’s Hospital, The University of Queensland, and AVATAR researchers from Griffith University, Australia, aimed to evaluate the efficacy of SecurAcath compared to traditional adhesive securement methods.

In this multi-center, randomized controlled trial involving 307 pediatric patients, SecurAcath exhibited a remarkable 4.4-fold reduction in catheter dislodgement rates (5.2%) compared to the adhesive device group (22.7%). The study also reported a 39% decrease in complications during catheter dwell, notably showing a 50% lower incidence of central line associated bloodstream infections (CLABSI) in the SecurAcath group.

Moreover, the comparative cost analysis revealed that SecurAcath could potentially save AU$36.60 (US$24.54) per use, making it not only clinically superior but also economically advantageous.

Tricia Kleidon, RN, MNursePrac, lead author of the study, emphasized, “The results of this study clearly show SecurAcath reduces dislodgement and saves money, therefore, SecurAcath should be used preferentially over adhesive device securement.”

Joe Goldberger, President and CEO of Interrad Medical, Inc., echoed these sentiments, stating, “This superiority evidence provides the strongest support to date that SecurAcath will become the new global standard for catheter securement.”

SecurAcath, the world’s only subcutaneous catheter securement device, offers lasting securement throughout the catheter's lifespan, significantly reducing the risk of infections and the need for costly catheter replacements. With 27 peer-reviewed scientific publications supporting its clinical and economic benefits, SecurAcath stands as a leader in catheter securement technology.

Click here for more information: https://www.businesswire.com/news/home/20240716891379/en/Interrad-Medical%E2%80%99s-SecurAcath-is-Superior-to-Standard-of-Care-in-Newly-Published-Randomized-Controlled-Clinical-Study